ANN – UBS rates the stock as Neutral

Ansell released a trading update that revealed organic sales growth in excess for H1, signalling EPS growth in the order of 62%-68% and with higher growth guidance for the full financial year, albeit without the usual H2 skew.

UBS analysts, in response, have increased forecasts by 4% for FY21, but only by 1-2% in following years. A stronger AUD is weighing down their valuation with the price target declining to $39.60 from $41.75. Neutral rating retained.

Sector: Health Care Equipment & Services.

 

Target price is $39.60.Current Price is $36.67. Difference: $2.93 – (brackets indicate current price is over target). If ANN meets the UBS target it will return approximately 7% (excluding dividends, fees and charges – negative figures indicate an expected loss).

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →